← Oncology Approval Tracker

FDA DECISION ·

Omisirge

omidubicel-onlv · Gamida Cell

FDA approvalNew therapyHematologic malignancies
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

To reduce time to neutrophil recovery and lower infection incidence in patients aged 12 or older with hematologic malignancies who are scheduled for cord blood transplant after myeloablative conditioning.

LAMPGEN ANALYSIS

Why it matters

The approval targeted engraftment and infection risk in patients undergoing cord blood transplantation.

What research teams should watch

Coordinate product availability, conditioning and transplant timing, with prespecified recovery and infection assessments.

PRIMARY RECORDS

Sources